Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1991-10-17
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0148-916X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
59
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
458-78
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1890370-Clofazimine,
pubmed-meshheading:1890370-Dapsone,
pubmed-meshheading:1890370-Drug Therapy, Combination,
pubmed-meshheading:1890370-Humans,
pubmed-meshheading:1890370-Leprosy,
pubmed-meshheading:1890370-Patient Compliance,
pubmed-meshheading:1890370-Rifampin,
pubmed-meshheading:1890370-World Health
|
pubmed:year |
1991
|
pubmed:articleTitle |
Impact of multidrug therapy on the treatment and control of leprosy.
|
pubmed:publicationType |
Editorial
|